At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Early Prescription of Immunosuppressants on First Three-year Course of Crohn's Disease
In Brief
A Phase 4 clinical trial evaluating early immunosuppressants (azathioprine, methotrexate) for Crohn's Disease. Completed, enrolled 120 participants across 26 sites.
Detailed Summary
Pluricentric randomized study comparing two therapeutic strategies at beginning of Crohn's disease: early immunosuppressants (prescription within the six first months following diagnosis) vs. conventional strategy (immunosuppressants given only in case of steroid failure, in a selected group of patients being at high risk of disabling course. The hypothesis is that immunosuppressants given early may improve the disease course during the 3 following years in this subset of patients.
Study Details
Timeline
Interventions
azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated